Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments

Antibody phage display technology has supported the emergence of numerous therapeutic antibodies. The development of bispecific antibodies, a promising new frontier in antibody therapy, could be facilitated by new phage display approaches that enable pairs of antibodies to be co-selected based on co-engagement of their respective targets. We describe such an approach, making use of two complementary leucine zipper domains that heterodimerize with high affinity. Phagemids encoding a first antibody fragment (scFv) fused to phage coat protein via the first leucine zipper are rescued in bacteria expressing a second scFv fused to the second leucine zipper as a soluble periplasmic protein, so that it is acquired by phage during assembly. Using a soluble scFv specific for a human CD3-derived peptide, we show that its acquisition by phage displaying an irrelevant antibody is sufficiently robust to drive selection of rare phage (1 in 10(5)) over three rounds of panning. We then set up a model selection experiment using a cell line expressing the chemokine receptor CCR5 fused to the CD3 peptide together with a panel of phage clones capable displaying either an anti-CCR5 scFv or an irrelevant antibody, with or without the capacity to acquire the soluble anti-CD3 scFv. In this experiment we showed that rare phage (1 in 10(5)) capable of displaying the two different scFvs can be specifically enriched over four rounds of panning. This approach has the potential to be applied to the identification of pairs of ligands capable of co-engaging two different user-defined targets, which would facilitate the discovery of novel bispecific antibodies.

[1]  P. Carter,et al.  Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.

[2]  Yves Poitevin,et al.  Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG , 2015, Nature Communications.

[3]  D. Christ,et al.  Bispecific antibodies with native chain structure , 2014, Nature Biotechnology.

[4]  R. Ladner,et al.  Drugs derived from phage display , 2014, mAbs.

[5]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[6]  Wolfgang Schaefer,et al.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies , 2012, mAbs.

[7]  F. Gueneau,et al.  Transferring the Characteristics of Naturally Occurring and Biased Antibody Repertoires to Human Antibody Libraries by Trapping CDRH3 Sequences , 2012, PloS one.

[8]  Jyoti Pande,et al.  Phage display: concept, innovations, applications and future. , 2010, Biotechnology advances.

[9]  L. Farinelli,et al.  By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection , 2010, Nucleic acids research.

[10]  M. Kosco‐Vilbois,et al.  Rapid, simple and high yield production of recombinant proteins in mammalian cells using a versatile episomal system. , 2010, Protein Expression and Purification.

[11]  F. Gueneau,et al.  Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent , 2009, mAbs.

[12]  A. Bradbury,et al.  Antibodies from phage antibody libraries. , 2004, Journal of immunological methods.

[13]  S. Sidhu,et al.  Bivalent antibody phage display mimics natural immunoglobulin. , 2004, Journal of immunological methods.

[14]  J. Osbourn Proximity-guided (ProxiMol) antibody selection. , 2002, Methods in molecular biology.

[15]  I. Pastan,et al.  Designed heterodimerizing leucine zippers with a ranger of pIs and stabilities up to 10−15 M , 2001, Protein science : a publication of the Protein Society.

[16]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[17]  Daniele Sblattero,et al.  Exploiting recombination in single bacteria to make large phage antibody libraries , 2000, Nature Biotechnology.

[18]  William C. Olson,et al.  Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.

[19]  M. Parmentier,et al.  Directed selection of MIP-1α neutralizing CCR5 antibodies from a phage display human antibody library , 1998, Nature Biotechnology.

[20]  J. Osbourn,et al.  Pathfinder selection: in situ isolation of novel antibodies. , 1998, Immunotechnology : an international journal of immunological engineering.

[21]  G. Walter,et al.  Phage diabody repertoires for selection of large numbers of bispecific antibody fragments , 1996, Nature Biotechnology.

[22]  R. Kontermann,et al.  A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Logtenberg,et al.  Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library (*) , 1996, The Journal of Biological Chemistry.

[24]  P. T. Jones,et al.  Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.

[25]  G. Winter,et al.  Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. , 1993, Nucleic acids research.

[26]  J. Tso,et al.  Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.

[27]  H R Hoogenboom,et al.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. , 1991, Nucleic acids research.

[28]  J. Vieira,et al.  Production of single-stranded plasmid DNA. , 1987, Methods in enzymology.